ERGI3 Polyclonal Antibody, Cy7 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-13103R-Cy7-100uL |
| Product Name | ERGI3 Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human ERGI3/ERGIC-3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 51614 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | 2310015B14Rik; AV318804; C20orf47; CGI 54; D2Ucla1; dJ477O4.2; DKFZp547A2190; Endoplasmic reticulum Golgi intermediate compartment protein 3; endoplasmic reticulum localized protein ERp43; Endoplasmic reticulum-Golgi intermediate compartment protein 3; ERGI3_HUMAN; ERGIC and golgi 3; ergic3; ERV46; NY BR 84; PRO0989; RP23-220D12.2; RP3-477O4.1; SDBCAG84; serologically defined breast cancer antigen 84; Serologically defined breast cancer antigen NY BR 84; Serologically defined breast cancer antigen NY-BR-84. |
| Background | Cycling proteins play important roles in the organization and function of the early secretory pathway by participating in membrane traffic and selective transport of cargo between the endoplasmic reticulum (ER), the intermediate compartment (ERGIC), and the Golgi. A family of membrane bound, ubiquitous proteins involved in the selective transport of newly synthesized glycoproteins from the ER to the ERGIC include VIP36, ERGIC-53, ERGIC-1, ERGIC-2 and ERGIC-3. ERGIC-1, also designated ERGIC32, is thought to modulate the activity of a complex formed by ERGIC-2, also designated Erv41, and ERGIC-3, also designated Erv46. ERGIC-2 and ERGIC-3 are both mammalian homologs of yeast proteins abundant in COPII-coated vesicles and localize to the Cis-face of the Golgi apparatus. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is ERGI3 Polyclonal Antibody, Cy7 Conjugated (bs-13103R-Cy7) validated for, and at what dilution?
bs-13103R-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-13103R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise ERGI3 Polyclonal Antibody, Cy7 Conjugated (bs-13103R-Cy7)?
KLH conjugated synthetic peptide derived from human ERGI3/ERGIC-3
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-13103R-Cy7)?
Cy7 on bs-13103R-Cy7: excitation / emission 743nm/767nm.